Published in Women's Health Weekly, January 18th, 2007
To date 34 women of the 39 enrolled have completed three months of dosing. Data from these women demonstrate that treatment with the highest dosage of Proellex (50 mg) achieved statistically significant pain reduction compared to treatment with Lucrin (Lupron), the current pharmaceutical standard of care for the treatment of endometriosis.
This European Phase II study compares three doses of double-blinded Proellex against open label Lucrin, a gonadotropin-releasing hormone (GnRH) agonist, for up to six months of treatment....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.